CD274 and non-small cell lung carcinoma: In our study, the positive rate of PD-L1 expression in KRAS mutant patients was as high as 70%, which had a significant immunotherapeutic benefit compared with mutation-negative NSCLC patients, and PFS also gradually prolonged with increasing PD-L1 expression levels.